Gemcitabine-induced reversible posterior leukoencephalopathy syndrome: A case report and review of the literature

Oncologist

Volumn 12, Issue 11, 2007, Pages 1332-1335

  Rajasekhar, Anita ^a   George Jr , Thomas J ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Cancer; Chemotherapy; Gemcitabine; Leukoencephalopathy; Neurotoxicity

Indexed keywords

ALPHA INTERFERON; ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CA 19-9 ANTIGEN; CISPLATIN; CYCLOSPORIN A; CYTARABINE; CYTOTOXIC AGENT; DEXAMETHASONE; ERLOTINIB; FLUOROURACIL; GEMCITABINE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; RITUXIMAB; SORAFENIB; TACROLIMUS;

AGED; ANAMNESIS; ARTERIOLE; ARTICLE; BRAIN DEATH; BRAIN RADIOGRAPHY; CANCER RADIOTHERAPY; CARDIOVASCULAR AUTOREGULATION; CASE REPORT; CENTRAL NERVOUS SYSTEM DISEASE; CEREBELLUM DISEASE; CLINICAL FEATURE; DRUG INHIBITION; DRUG STRUCTURE; DRUG WITHDRAWAL; FALLING; FEMALE; HUMAN; HYPERTENSION; LABORATORY TEST; LEUKOENCEPHALOPATHY; MEDICAL LITERATURE; MENTAL DISEASE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ADENOCARCINOMA; PATIENT CARE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SOMNOLENCE; TREATMENT OUTCOME; TREATMENT RESPONSE; WHITE MATTER;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BRAIN; CENTRAL NERVOUS SYSTEM; DEOXYCYTIDINE; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MEDICAL ONCOLOGY; NEOPLASMS; POSTERIOR LEUKOENCEPHALOPATHY SYNDROME; RISK FACTORS; TREATMENT OUTCOME;

EID: 36849002282     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.12-11-1332     Document Type: Article

References (23)

1. Burris HA 3rd, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997;15:2403-2413.
2. Brodowicz T, Krzakowski M, Zwitter M et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial. Lung Cancer 2006;52(suppl 2):155-163.
3. Delfino C, Caccia G, Gonzáles LR et al. Gemcitabine plus paclitaxel as first-line chemotherapy for patients with advanced breast cancer. Oncology 2004;66:18-23.
4. Albain KS. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival. J Clin Oncol 2004;22(14 suppl):510.
5. Pfisterer J, Plante M, Vergote I et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006;24:4699-4707.
6. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-1966.
7. Hui YF, Reitz J. Gemcitabine: A cytadine analogue active against solid tumors. Am J Health Syst Pharm 1997;54:162-170.
8. Baker WJ, Royer GL Jr, Weiss RB. Cytarabine and neurologic toxicity. J Clin Oncol 1991;9:679-693.
9. Plunkett W, Huang P, Xu YZ et al. Gemcitabine: Metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995;22(suppl 11):3-10.
10. Saito B, Nakamaki T, Nakashima H et al. Reversible posterior leukoencephalopathy syndrome after repeat intermediate-dose cytarabine chemotherapy in a patient with acute myeloid leukemia. Am J Hematol 2007;82:304-306.
11. Eli Lilly and Company. Gemzar® (gemcitabine HCl for injection) [package insert]. Indianapolis, IN: Eli Lilly and Company, 2006.
12. Davis JR, Fernandes C, Zalcberg J. Gemcitabine and the blood brain barrier. Aust N Z J Med 1999;29:831-832.
13. Russell MT, Nassif AS, Cacayorin ED et al. Gemcitabine-associated posterior reversible encephalopathy syndrome: MR imaging and MR spectroscopy findings. Magn Reson Imaging 2001;19:129 -132.
14. Larsen FO, Hansen SW. Severe neurotoxicity caused by gemcitabine treatment. Acta Oncol 2004;43:590-591.
15. Hinchey J, Chaves C, Appignani B et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996;334:494-500.
16. Casey SO, Sampaio RC, Michel E et al. Posterior reversible encephalopathy syndrome: Utility of fluid-attenuated inversion recovery MR imaging in the detection of cortical and subcortical lesions. AJNR Am J Neuroradiol 2000;21:1199-1206.
17. Rangi PS, Partridge WJ, Newlands ES et al. Posterior reversible encephalopathy syndrome: A possible late interaction between cytotoxic agents and general anesthesia. Neuroradiology 2005;47:586-590.
18. Tam CS, Galanos J, Seymour JF et al. Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies. Am J Hematol 2004;77:72-76.
19. Allen JA, Adlakha A, Bergethon PR. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol 2006;63:1475-1478.
20. Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006;354:980-982.
21. Govindarajan R, Adusumilli J, Baxter D et al. Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006. J Clin Oncol 2006;24:28:e48.
22. Irvin W, MacDonald G, Smith JK et al. Dexamethasone-induced posterior reversible encephalopathy syndrome. J Clin Oncol 2007;25:2484-2486.
23. Mavragani CP, Vlachoyiannopoulos PG, Kosmas N et al. A case of reversible posterior leucoencephalopathy syndrome after rituximab infusion. Rheumatology (Oxford) 2004;43:1450-1451.